Compare M&T Bank Corporation (MTB) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Natera Inc. Common Stock — how do they compare? M&T Bank Corporation trades at $215.86 (market cap $31.47B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and M&T Bank Corporation pays a 2.75% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold M&T Bank Corporation for 99 Days and Natera Inc. Common Stock for 0 Days on average.
| MTB | NTRA | |
|---|---|---|
Market Cap | $31.47B | $57.03B |
Volume | 743,357 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $254.09 | $425.64 |
52-Week Low | $178.63 | $179.42 |
Typical Hold Time | 99 Days | 0 Days |
Enterprise Value | $47.83B | $56.18B |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank Corporation (MTB) trades at $216.05, down 1.75% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026), a P/E of 11.54, and net income margin of 30.85%. Recent developments include a new Connecticut branch opening and AI investments to drive loan growth. Cash flow trends show operational strength despite negative net cash flow in 2025.
MTB presents a value opportunity with attractive valuation metrics and dividend stability, though technical weakness and competitive banking pressures pose near-term risks. Analyst consensus targets $258.92 (19.8% upside) with 31% buy ratings, but investors should monitor loan growth execution and interest rate sensitivity.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
